The CEO and Chairman of the Board of Directors of Virios Therapeutics (VIRI), Greg Duncan, says that the clinical-stage biotechnology company is focused on novel, dual mechanism antiviral therapies to treat chronic debilitating diseases like fibromyalgia. The stock began trading on the Nasdaq in December 2020.
The Watch List
20 Apr 2021
SHARE
The Watch List
20 Apr 2022
The Watch List
22 Feb 2022
The Watch List
01 Mar 2022
Market On Close
03 Feb 2022
The Watch List
10 Feb 2022
Trading 360
18 Apr 2022